iiinova — where your digital self keeps evolving

JAMA Cardiology @jamacardiology.com · 07/10/2026

💬 Viewpoint: In #Cardiology, shrinking newsrooms, social media, and #AI may erode independent medical #journalism and blur the line between reporting, promotion, and opinion. ja.ma/4zitWvc

JAMA Cardiology webpage displays a Viewpoint article: 'The Need for Cardiology News Coverage' by Shelley Wood, MJ¹. Published Online: Oct 7, 2026. DOI: 10.1001/jamacardio.2026.3978. Navigation and engagement icons are visible.

000

JAMA Cardiology @jamacardiology.com · 07/10/2026

Meta-analysis: In adults with and without #ChronicKidneyDisease, intensive blood pressure lowering reduced major cardiovascular events by 15% per 10-mm Hg lower systolic blood pressure. ja.ma/4hxhSAp

JAMA Cardiology original investigation: "Intensive vs Standard Blood Pressure Lowering in People With and Without Chronic Kidney Disease: A Systematic Review and Meta-Analysis." Authors include Fotini Iatridi, Alistair J. Roddick, Natalie Staplin, and others.

020

JAMA Cardiology @jamacardiology.com · 01/10/2026

💬 Editorial: A once-daily #HeartFailure polypill improved adherence and reduced pill burden vs usual care in a randomized implementation trial in Sri Lanka. ja.ma/3VYHk9o

JAMA Cardiology Editorial titled: A Polypill Strategy to Close the Heart Failure Treatment Gap. Authored by Gregg C. Fonarow, MD, and John J. V. McMurray, MD. Published Online: September 30, 2026.

000

JAMA Cardiology @jamacardiology.com · 01/10/2026

Among patients hospitalized for #HeartFailure, most had multiple overlapping #CardiovascularKidneyMetabolic conditions, and increasing multimorbidity was associated with higher mortality and readmission risk. ja.ma/4xRFjJC

Three bar charts display patient percentages for HFrEF, HFmrEF, and HFpEF by comorbidity combination. Colors distinguish the number of cardiometabolic kidney morbidities (CKMs) from 'HF only' to '4 CKM'. The highest percentages occur with multiple CKMs.

011

JAMA Cardiology @jamacardiology.com · 30/09/2026

💬 Editorial: Global #HeartFailure prevalence has increased substantially, and better prevention of hypertension, ischemic heart disease, and rheumatic heart disease may help reduce future burden. ja.ma/4iSkKZJ

JAMA Cardiology web page shows an Editorial: 'A Recipe for Estimating the Global Burden of Heart Failure' by Philip Joseph, MD, & Isabelle Johansson Bartolini, PhD. Published Online: September 30, 2026. DOI: 10.1001/jamacardio.2026.4084.

000

JAMA Cardiology @jamacardiology.com · 30/09/2026

Globally, #HeartFailure affected an estimated 56 million people in 2023, with increasing burden largely associated with population growth and aging. ja.ma/4AVWa0G

JAMA Cardiology article, pub. Sep 30, 2026: 'Global Burden of Heart Failure, 1990-2023'. A stacked bar graph shows global HF etiologies by age in 2023. Ischemic heart disease dominates older age groups; congenital heart anomalies are prominent in younger ages.

000

JAMA Cardiology @jamacardiology.com · 23/09/2026

Among patients with #HeartFailure and left ventricular ejection fraction ≥40%, undiagnosed #ChronicKidneyDisease was common and was associated with higher cardiovascular death and total heart failure event rates vs no chronic kidney disease. ja.ma/4yPW4Wi

000

JAMA Cardiology @jamacardiology.com · 23/09/2026

Among older adults, worsening #Frailty, lower intrinsic capacity, and poorer physical health-related quality of life preceded #CardiovascularDisease events and accelerated in the 5 years before onset. ja.ma/4ryGvQI

Four line graphs show mean trajectories for frailty index, Fried phenotype frailty, modified intrinsic capacity, and physical health-related quality of life. For CVD cases (orange lines) versus controls (blue lines), frailty measures increase, and capacity/quality of life measures decrease more sharply as time approaches the incident CVD event (year 0).

000

JAMA Cardiology @jamacardiology.com · 18/09/2026

BLE-enabled #Pacemakers broadcast unique identifiers and were detectable at distances substantially greater than those used clinically in ex vivo testing, raising privacy and cybersecurity concerns. ja.ma/4huKEkX

Night scene: experimental setup on a snowy urban sidewalk. A large gridded antenna on a tripod, labeled 'Antenna', points down a path towards indicated 'CIEDs'. Bare trees, parked cars, and distant city lights are visible.

000

JAMA Cardiology @jamacardiology.com · 17/09/2026

📝 Viewpoint: #CoronaryComputedTomographyAngiography plaque analysis has prognostic value, but current evidence does not support its use as a screening tool for asymptomatic adults. ja.ma/3UW7RUt

JAMA Cardiology article titled "Viewpoint: Coronary Computed Tomography Angiography and Plaque Analysis for Screening" by Alexander R. Zheutlin, Jared A. Spitz, and John T. Wilkins. Published online September 16, 2026.

000

JAMA Cardiology @jamacardiology.com · 17/09/2026

🧬 Viewpoint: Current therapies for #InheritedCardiomyopathy do not prevent progressive heart failure, but #GeneticTherapy may offer future approaches that target the underlying molecular cause of disease. ja.ma/46M9jvv

Genetic mechanisms of inherited cardiomyopathies. Compares Health (normal protein), Haploinsufficiency (reduced protein, stop codon), & Dominant Negative (disrupted protein, missense). Visuals show DNA, amino acids, protein pools (normal, fewer, abnormal), plus genes & therapies (gene delivery, variant correction).

000

JAMA Cardiology @jamacardiology.com · 09/09/2026

In patients with #Cancer, immune checkpoint inhibitors, vascular endothelial growth factor inhibitors, or both were not associated with increased arterial inflammation on #Fluorodeoxyglucose positron emission tomography computed tomography at 24 weeks. ja.ma/4r4stpE

Figure 2: Four box plots show the change in Maximal Tissue to Background Ratio (TBRmax) over time. Subplots compare ICI, VEGFI, and ICI+VEGFI groups based on A) artery size (Aorta, Carotid/iliac), B) arterial calcification, C) atherosclerotic cardiovascular disease (ASCVD), and D) immunosuppression.

010

JAMA Cardiology @jamacardiology.com · 29/08/2026

🩺 In Japan, elective #AtrialFibrillation ablation was associated with low in-hospital mortality during a decade of rapid expansion, with no evidence that broader adoption reduced procedural safety. #ESCCongress ja.ma/4xklafG

Line graph: In-hospital mortality after elective atrial fibrillation ablation, 2012-2022. Y-axis: mortality percentage. Orange line: annual mortality (fluctuating, peak ~0.07%, low ~0.02%). Dark line with grey area: 3-year moving average, showing a downward trend. P for trend = .04.

010

JAMA Cardiology @jamacardiology.com · 28/08/2026

💬 Editorial: In #TransthyretinCardiacAmyloidosis, machine learning-based risk prediction may improve baseline prognostic assessment compared with static National Amyloidosis Centre and Mayo staging systems in treated populations. #ESCCongress ja.ma/4ccVOYP

Figure: From Static Staging to Dynamic Risk Prediction in ATTR-CM. Flowchart compares Eras (Pretherapy, Treated, Therapeutic), Inputs (biomarkers, imaging), Outputs (prognostic stage, risk score, updated risk), Limitations, & Clinical Questions across these three methods.

000

JAMA Cardiology @jamacardiology.com · 28/08/2026

In patients with #TransthyretinCardiacAmyloidosis, a machine learning-based model predicted all-cause mortality and #HeartFailure hospitalization more accurately than the National Amyloidosis Centre and Mayo Clinic staging systems. #ESCCongress ja.ma/4xo8STz

Table 3: Discrimination performance of RSF model compared with Mayo Clinic and NAC staging scores. Data shows Concordance index (Harrell, Uno, Antolini) and AUC (1y, 2y, 3y) across Bern-Swiss, Other-Swiss, and Vienna cohorts. RSF generally exhibits higher performance.

010

JAMA Cardiology @jamacardiology.com · 28/08/2026

💬 Editorial: #AI-guided #Echocardiography for #AorticStenosis could help nonexpert operators identify patients who need comprehensive imaging, with potential to expand screening where expert access is limited. #ESCCongress ja.ma/4qGJs13

Editorial article: "Artificial Intelligence for Acquisition and Interpretation of Echocardiography—Closing the Loop" by Thomas H. Marwick. Discusses AI's role in cardiology for diagnosing aortic stenosis and improving echocardiography, including detailed data. Published in JAMA Cardiology on Aug 28, 2026.

000

JAMA Cardiology @jamacardiology.com · 28/08/2026

An #AI model applied to #FocusedCardiacUltrasound accurately detected moderate or greater #AorticStenosis, including in examinations acquired by novice operators. #ESCCongress ja.ma/4y5Dd9s

AI-guided 2-step screening workflow for Aortic Stenosis. 1302 participants screened by novices. AI review: 1171 no AS, 487 AS, 44 uninterpretable. 10.1% overread by cardiologist. 4.8% referred for formal echo. AS detection: sensitivity 85.4%, specificity 99.7%.

000

JAMA Cardiology @jamacardiology.com · 28/08/2026

Figure: From Static Staging to Dynamic Risk Prediction in Transthyretin Amyloid Cardiomyopathy (ATTR-CM). A table comparing three risk prediction methods (Static, ML global, Dynamic) across their Era, Inputs (e.g., biomarkers), Outputs (e.g., risk scores), Limitations, and Clinical questions.

000

JAMA Cardiology @jamacardiology.com · 28/08/2026

Table 3: Discrimination Performance of the RSF Model Compared With Mayo Clinic and NAC Staging Scores. It details concordance index & AUC for 'Score' and 'RSF' models across three cohorts, showing RSF generally outperforms 'Score' for both staging systems.

000

JAMA Cardiology @jamacardiology.com · 28/08/2026

A new study suggests machine learning may improve risk prediction in patients with ATTR-CM. #Amyloidosis #MachineLearning #Cardiology #ESCCongress 📖 Read the full article to learn more: ja.ma/4gjPCka

000

JAMA Cardiology @jamacardiology.com · 28/08/2026

Figure on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) risk prediction. It illustrates the evolution from Static Staging to ML Global Prediction to Dynamic Prediction, covering eras, inputs, outputs, limitations, and clinical questions.

000

JAMA Cardiology @jamacardiology.com · 28/08/2026

Table 3 displays the discrimination performance of the RSF model versus Mayo Clinic and NAC staging scores. It shows concordance index (Harrell, Uno, Antolini) and AUC (1y, 2y, 3y) values for 'Score' and 'RSF' across Bern-Swiss, Other-Swiss, and Vienna cohorts.

000

JAMA Cardiology @jamacardiology.com · 28/08/2026

Editorial titled "Artificial Intelligence for Acquisition and Interpretation of Echocardiography—Closing the Loop" by Thomas H. Marwick, MBBS, PhD, MPH. This article discusses AI's role in cardiac ultrasound for improved screening and diagnosis.

020

JAMA Cardiology @jamacardiology.com · 28/08/2026

An #AI model applied to #FocusedCardiacUltrasound accurately detected moderate or greater #AorticStenosis, including in examinations acquired by novice operators. #ESCCongress ja.ma/4zHIoOo

AI-guided 2-step screening workflow for moderate aortic stenosis. 1302 participants scanned by novices. AI review: 1171 no AS (stop), 487 AS, 44 uninterpretable. 10.1% overread by cardiologist. Resulting in 4.8% referred for formal echo. Detection: sensitivity 85.4%, specificity 99.7%, PPV 91.1%, NPV 99.4%.

000

JAMA Cardiology @jamacardiology.com · 28/08/2026

An editorial article titled 'Artificial Intelligence for Acquisition and Interpretation of Echocardiography—Closing the Loop' by Thomas H. Manwick, MBBS, PhD, MPH, in the 'AI in Cardiology' section.

010

JAMA Cardiology @jamacardiology.com · 28/08/2026

An #AI model applied to #FocusedCardiacUltrasound accurately detected moderate or greater #AorticStenosis, including in examinations acquired by novice operators. #ESCCongress ja.ma/4qHYBPx

Flowchart shows an AI-guided 2-step screening workflow for moderate Aortic Stenosis using novice-operated FoCUS. Of 1302 participants, 1171 were AI: no AS. AI: AS (487) & uninterpretable (44) cases undergo 10.1% cardiologist overread, leading to 4.8% referred for formal echo. Sensitivity 85.4%, specificity 99.7%.

020

JAMA Cardiology @jamacardiology.com · 19/08/2026

💬 Viewpoint: #CardiovascularDisease during #Pregnancy and the postpartum period is becoming more common and more complex, but evidence guiding prevention, diagnosis, and management remains limited. ja.ma/4xd3wuq

JAMA Cardiology article webpage. Viewpoint on Women's Health: "Maternal Cardiovascular Disease—Time to Close the Evidence Gap." Authors include Upasana Tayal, Claire Sheppard, Deborah A. Lawlor. Published online August 19, 2026.

010

JAMA Cardiology @jamacardiology.com · 19/08/2026

This case report discusses intravascular lithotripsy and resultant ventricular fibrillation in a man in his 70s with severely calcified right coronary artery stenosis. ja.ma/4gtjYzE

A: Grayscale fluoroscopy for intravascular lithotripsy shows a catheter in a vessel. B: Electrocardiography. ECG traces A, B, III transition from regular rhythm to rapid, irregular activity (asterisks, arrowhead). The arterial pressure (AO) waveform shows a significant drop.

000

JAMA Cardiology @jamacardiology.com · 19/08/2026

Among patients with #TransthyretinAmyloidosis with cardiomyopathy, impaired left atrial strain on #Echocardiography was associated with higher risk of death, cardiovascular events, heart failure hospitalization, and atrial fibrillation. ja.ma/4gpsqji

Forest plot showing HR (95% CI) for Left Atrial Strain (LAS), LA Volume Index (LAVI), and A-Wave Velocity versus Clinical Outcomes. Multiple outcomes (CV events, death, HF hospitalizations, AF/AFI) are listed. Many LAS and A-wave velocity metrics show increased risk (HR>1) for adverse outcomes.

000

JAMA Cardiology @jamacardiology.com · 12/08/2026

Among patients with Transthyretin amyloid cardiomyopathy, #vutrisiran was associated with favorable changes in cardiac structure, function, and amyloid burden on serial cardiovascular magnetic resonance imaging compared with placebo. ja.ma/4i42ps7

Cardiac MRI scans for 3 patients with Wild-Type Transthyretin Amyloid Cardiomyopathy (ATTR-CM), showing baseline and 36-month progression. False-color heart images display ECV %. P1: 61% to 55%; P2: 54% to 48%; P3: 49% to 55%.

000

JAMA Cardiology @jamacardiology.com · 10/08/2026

📝 JAMA Cardiology Review: Interatrial dyssynchrony from disease or conventional pacing delays left atrial activation and may raise arrhythmia risk; optimized pacing strategies are an active area of research. ja.ma/4fTlA5i

Diagram shows atrial conduction pathways in a heart (A), and intrinsic atrial activation patterns with corresponding ECG P-wave morphologies (B). Normal activation has a single P-wave (<0.10s). Partial interatrial block shows a bifid P-wave (>0.12s), and advanced block shows two distinct P-wave humps (>0.12s).

000

JAMA Cardiology @jamacardiology.com · 09/08/2026

Among statin-intolerant adults at high cardiovascular risk, #BempedoicAcid was associated with reduced risk of #VenousThromboembolism, including deep vein thrombosis and pulmonary embolism. ja.ma/4fTbd1i

Kaplan-Meier plot shows cumulative incidence of venous thromboembolism. The Bempedoic acid curve (dark blue) indicates a lower incidence than the Placebo curve (orange) over 54 months. HR 0.58; 95% CI 0.39-0.86; P = .006. Numbers at risk are provided below the graph.

000

JAMA Cardiology @jamacardiology.com · 08/08/2026

In patients with obstructive #hypertrophic #cardiomyopathy, aficamten improved exercise measures, including peak oxygen uptake and recovery, compared to metoprolol, supporting its use as first-line therapy for symptomatic oHCM. ja.ma/4fLrfvu

Bar graph: Responder Analyses of Categorical Change in Peak Oxygen Uptake (pVO₂) with Aficamten vs Metoprolol at 24 Weeks. Metoprolol group shows higher rates of deterioration, while Aficamten shows higher rates of improvement across categories.

001

JAMA Cardiology @jamacardiology.com · 08/08/2026

Among patients hospitalized with #HeartFailure, both a small left ventricle and a large left ventricle were associated with higher all-cause mortality vs normal size, showing a U-shaped association between left ventricular end-diastolic diameter and risk. ja.ma/4fJDqc9

Six graphs showing LVEDD (mm) vs. Hazard Ratio (HR) for all-cause & cardiovascular mortality in hospitalized patients, males, & females. Histograms show population distribution. HR curves are U-shaped, with min HR around 40-50mm. P overall <.001, P nonlinear <.001.

000

JAMA Cardiology @jamacardiology.com · 08/08/2026

Both #NonHDLCholesterol and #ApolipoproteinB provided independent, clinically important information for predicting #AtheroscleroticCardiovascularDisease risk, supporting joint assessment of cholesterol content and particle number in risk evaluation. ja.ma/4wORcQX

Four plots show hazard ratios increasing for myocardial infarction & ASCVD with higher Non-HDL cholesterol & Apolipoprotein B. Population distribution also shown. N=93810 (2462 MI events), N=93521 (5723 ASCVD events).

000

JAMA Cardiology @jamacardiology.com · 05/08/2026

000

JAMA Cardiology @jamacardiology.com · 03/08/2026

From JAMA: Among patients undergoing elective cardiac surgery, perioperative #dapagliflozin reduced postoperative #AcuteKidneyInjury compared with placebo over 7 days. ja.ma/4wnKyA9

JAMA study on dapagliflozin for acute kidney injury (AKI) after elective cardiac surgery. 784 patients randomized. Dapagliflozin (28% AKI) vs. Placebo (52% AKI). Dapagliflozin significantly reduced postoperative AKI incidence by 23.98%.

000

JAMA Cardiology @jamacardiology.com · 03/08/2026

📑 JAMA Cardiology Patient Page: New fatigue, shortness of breath, chest discomfort, dizziness, or leg swelling during or after #BreastCancer treatment may signal #HeartDisease and warrant prompt evaluation. ja.ma/4yLpMwu

A distressed older woman, eyes closed, with a glowing heart visible in her chest. Text states: "Breast cancer and heart disease may be linked and share common risk factors." It details how cancer treatments can cause heart problems & lists symptoms like fatigue, chest pain. "Do not delay if concerned about symptoms. Early detection can save lives."

000

JAMA Cardiology @jamacardiology.com · 30/07/2026

In patients with #TransthyretinAmyloidCardiomyopathy, acoramidis improved #HeartFailure-related health status vs placebo, with a 9.9-point benefit in Kansas City Cardiomyopathy Questionnaire Overall Summary score at 30 months. ja.ma/3U3v6eF

Figure 2. Bar graph: KCCQ score changes from baseline to month 30. Acoramidis (dark teal, n=409) vs. Placebo (orange, n=202). Placebo shows greater mean score improvement in most domains like Physical & Social limitation and overall summary scores. Acoramidis shows better QoL & Self-efficacy.

010

JAMA Cardiology @jamacardiology.com · 29/07/2026

Among asymptomatic patients with #MitralRegurgitation managed medically, 5-year survival declined from 88% with effective regurgitant orifice area <20 mm2 to 72% with 20-39 mm2 and 55% with >40 mm2. ja.ma/44YzOwH

MR severity classification by scatter plot and table. The plot shows Regurgitant Volume (RVOL) vs. Effective Regurgitant Orifice Area (ERO), with points colored by ERO severity. A strong positive correlation is evident. The table summarizes classification counts across mild, moderate, and severe ERO and RVOL levels.

110

JAMA Cardiology @jamacardiology.com · 29/07/2026

💬 Viewpoint: #CardioOncology needs to move beyond consensus-driven surveillance toward prospective trials, risk stratification, and clinically meaningful cardiovascular end points in patients with #Cancer. ja.ma/3S1I8J9

JAMA Cardiology article page, featuring the Viewpoint titled "The Next Phase of Cardio-Oncology—From Consensus to Science" by Javid J. Moslehi, MD. Published online July 29, 2026. Page includes journal title, navigation, and article details.

000

JAMA Cardiology @jamacardiology.com · 23/07/2026

Figure 1 from JAMA Cardiology shows atrial conduction pathways in a heart (A), detailing nodes & bundles. Panel B illustrates normal, partial, and advanced interatrial block, comparing atrial activation patterns with corresponding P-wave morphologies and durations (<0.10s, >0.12s).

000

JAMA Cardiology @jamacardiology.com · 23/07/2026

Among adults with asymptomatic severe #AorticStenosis, 15% had a positive treadmill stress test, but 20% of these patients remained untreated at 1 year despite AVR indications. ja.ma/4ffwC5J

Kaplan-Meier curves show 2-year all-cause mortality for AS patients with positive treadmill stress test. Panel A: overall mortality rises over 24 months. Panel B: stratified by stress test criteria, mortality is highest for symptoms, then SBP drop, lowest for arrhythmias (P=.64).

000

JAMA Cardiology @jamacardiology.com · 22/07/2026

A digitally enabled quality improvement strategy modestly improved #LDL_C control and increased prescription of combination lipid-lowering therapy for patients with #ASCVD, but many remained above guideline targets. ja.ma/4yxMEiP

JAMA Cardiology RCT: Digital intervention significantly lowered LDL-C in 1465 adults (mean age 62.3y) with atherosclerotic cardiovascular disease. LDL-C at 6 months: Intervention ~77 mg/dL, Usual Care ~85 mg/dL. Adjusted diff: -6.62 mg/dL (P=.004).

000

JAMA Cardiology @jamacardiology.com · 16/07/2026

The LDL-C–MH-MARS machine learning equation matched the Martin-Hopkins equation for #LDL_C accuracy and outperformed Friedewald, Sampson-NIH, and Modified Sampson equations in nearly 5 million US patients. ja.ma/4hee7Qq

Two bar graphs display concordance of estimated vs measured LDL-C. Graph A, from a reference lab (TG <400 mg/dL), compares Friedewald, Sampson-NIH, Martin-Hopkins, & MARS methods across LDL-C categories. Graph B, FOURIER, presents similar data for <20 & 20-39 mg/dL.

010

JAMA Cardiology @jamacardiology.com · 15/07/2026

💬 Editorial: Slowed declines in US #IHD mortality are linked to rising obesity and glucose intolerance, contributing to lower life expectancy and healthy years compared with other high-income countries. ja.ma/4wOnawg

JAMA Cardiology editorial: 'Reigniting the Effort to Prevent Premature Death and Extend Healthy Life Span' by Robert M. Califf, MD, MACC. Published online July 15, 2026. DOI: 10.1001/jamacardio.2026.2446.

000

JAMA Cardiology @jamacardiology.com · 15/07/2026

In 2023, nearly 89% of #IHD deaths in the US were attributable to modifiable risks, with high blood pressure, diet, and high low-density lipoprotein cholesterol as the top contributors. ja.ma/3TAW794

Twelve choropleth maps of the US show state-level percentages for various health risk factors (e.g., high blood pressure, cholesterol, BMI, kidney dysfunction) and environmental exposures (e.g., dietary risks, tobacco, lead, pollution), using diverse color gradients.

010

JAMA Cardiology @jamacardiology.com · 12/07/2026

Maternal diabetes during pregnancy was associated with increased risk of overall #CardiovascularDisease and specific CVD subtypes in offspring, with congenital heart disease, preterm birth, and large for gestational age mediating part of the association. ja.ma/3SXNAgj

Webpage for JAMA Cardiology article: "Maternal Diabetes and Risk of Early-Onset Cardiovascular Diseases in Offspring" by Xingbo Mo, Imre Janszky, Hui Wang, et al. Published May 13, 2026. DOI: 10.1001/jamacardio.2026.0915.

001

JAMA Cardiology @jamacardiology.com · 11/07/2026

In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone consistently lowered systolic blood pressure and reduced cardiovascular deaths and heart failure events, independent of baseline blood pressure. ja.ma/4aGWWD8

Two bar graphs show Finerenone treatment effects on cardiovascular events based on baseline SBP (P=.96) and DBP (P=.83). Both graphs display a distribution of baseline blood pressure, with a generally stable treatment effect (around 1.1, marked by an orange line) across different pressure ranges.

000

JAMA Cardiology @jamacardiology.com · 11/07/2026

Heat-attributable #CardiovascularDisease burden in the US may triple by 2050, with population aging and income disparities amplifying risk, highlighting the need for targeted heat mitigation in vulnerable communities. ja.ma/4eUTCH7

JAMA Cardiology: 'Projected US Cardiovascular Disease Burden From Heat Exposure.' Figure 3 shows three bar charts. A: US population ages, with 65+ percentage rising from 2016 to 2095. B: DALY per 100,000 highest for age 65+. C: Total heat-attributable DALYs (life-years) are greater with demographic aging and higher GHG scenarios.

010